Porsolt Expands its In Vitro Drug Discovery Service Capabilities with the Acquisition of Fluofarma PR Newswire LAVAL, France, December 10, 2015 LAVAL , France , December 10, 2015 /PRNewswire/ — Porsolt SAS, a preclinical in vivo efficacy and safety CRO, has acquired Fluofarma, a Bordeaux -based company focused on the provision of cell-based assays and in vitro screening services. The acquisition further expands Porsolt’s capabilities and services that can assist clients at earlier stages of their drug discovery programs. Fluofarma, established in 2003, specializes in providing tailored services in cell biology and high content analysis, an approach highly solicited in association with predictive tools and cell-based models, thereby fulfilling pharmaceutical industry requirements to optimize the drug discovery pipeline. […]